Triple Analysis: Lung Cancer, Prostate Cancer and Angiogenesis
BioSeeker Group AB
January 30, 2012 3865 Pages - SKU: BIOS6796218
|
|
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.This part is based on the following publication:Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
Part II: Prostate Cancer
The prostate cancer report part comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. This report part extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and assesses them in prostate cancer.This part is based on the following publication:A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market
Part III: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.This part is based on the following publication:Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area strategies
- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.
|
- Key Topics Covered:
- Part I: Lung Cancer
- 5.1 The Scope of this Report 31
- 6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
- 7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
- 8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
- 9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
- 11 Disclaimer 1300
- 12 Drug Index 1301
- 13 Company Index 1314
- Figures: Includes 7 Figures
- Tables: Includes 284 Tables
- Total Number of Pages: 1323
- Part II: Prostate Cancer
- 5.1 The Scope of this Report 28
- 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (202 Drug Targets) 32-383
- 7 Emerging New Products to Established Ones: Drug Target Strategies by their Highest Stage of Development in the Prostate Cancer Pipeline (187 Drug Target Strategies and 346 Drugs) 384-438
- 8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 439-485
- 9 Pipeline and Portfolio Planning: Competitive Benchmarking of Prostate Cancer Therapeutic Pipeline by Investigator (198 Investigators) 486-820
- 11 Drug Index 822
- 12 Company Index 831
- Figures: Includes 6 Figures
- Tables: Includes 257 Tables
- Total Number of Pages: 838
- Part III: Angiogenesis
- 5.1 The Scope of this Report 37
- 6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
- 7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
- 8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
- 9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
- 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
- 12 Drug Index 1687
- 13 Company Index 1697
- Figures: Includes 7 Figures
- Tables: Includes 310 Tables
- Total Number of Pages: 1,704
Share this report
Other tasks Related Markets Oncology/Hematology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
